Literature DB >> 32948995

Post COVID-19 longitudinally extensive transverse myelitis (LETM)-a case report.

Seyed Mohammad Baghbanian1,2, Farzaneh Namazi3,4.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32948995      PMCID: PMC7500496          DOI: 10.1007/s13760-020-01497-x

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


× No keyword cloud information.
Dear editor A 53-year-old female was admitted to the neurology ward of Booalisina hospital Sari, Iran after suffering from paraparesis for 2 days. The patient's symptoms started with distal left limb involvement, and after a few hours, the right lower limb was also involved. The symptoms were fully established within 2 days. Three days before the weakness of the lower limbs, the patient suffered from radicular low back pain and transient urinary incontinence. The patient had a history of diabetes mellitus, hypertension, and ischemic heart disease. The systemic examination was normal. Her neurological examination demonstrated asymmetrical hypotonic paraparesis 3/5 power in the proximal and distal part of the right lower limbs and 0/5 power in the proximal and distal part of left lower limbs with areflexia and bilateral Babinski sign. Sensory examination revealed a sensory level at T11–T12 to pinprick testing and bilateral position test impairment in the bilateral lower extremities. The tendon reflexes in both upper limbs and cranial nerve examination were normal. 2 weeks before, the patient had been admitted and treated for COVID-19 and at that time the results of coronavirus RNA nasopharyngeal swab reported positive. Chest CT revealed a patchy ground-glass consolidation in the middle and lower lobes of the right lung (Fig. 1). CSF testing showed 13 cells predominantly lymphocytes with normal protein and glucose. CSF OCB reported negative and the IgG index was in the upper limit of normal (0.71). Brain MRI was normal and spinal cord MRI showed a longitudinally extensive transverse myelitis in the T8-T10 cord segments (Fig. 2). Without corticosteroid therapy, plasmapheresis was done and paresis recovered to a certain degree. The patient was discharged and referred for rehabilitation treatment.
Fig. 1

Middle and lower lob of the lung involvement in high resolution lung CT scan

Fig. 2

longitudinally thorasic extensive transverse myelitis T2sagital spinal cord MRI

Middle and lower lob of the lung involvement in high resolution lung CT scan longitudinally thorasic extensive transverse myelitis T2sagital spinal cord MRI Central nervous system involvement in COVID disease occurs hematogenously or by neuronal retrograde or antegrade polarization via peripheral nerves, nucleus solitaries of the brain stem, spinal cord, olfactory and trigeminal system [1]. Post-infection myelitis was reported in a confirmed COVID patient with high fever, bone marrow suppression, and liver function failure. It is interpreted that immune damage in the early stage of COVID might be explained the myelitis [2]. In our patient after 14 days of the initial phase of COVID infection, myelitis presented without any signs of acute infection. No significant abnormality was seen in laboratory tests. Liver function tests, Anti NMO Ab, Anti MOG Ab, and CSF PCR for cytomegalovirus and herpes simplex virus were negative. CSF PCR for the COVID-19 virus was negative. Acute disseminated encephalomyelitis (ADEM) which presents after a systemic infection may present with LETM but ADEM without brain involvement is unusual. IL-6 plays a key role in the second attack of COVID disease which begins 7–14 days after the first respiratory presentation. Although increase IL-6 induces B-cells differentiation and has an anti-inflammatory effect, it could cause acute phase cytokine overproduction and cytokine release syndrome (cytokine storm) associated with fever and multiple organ failure [3]. Guillain-Barré Syndrome associated with COVID infection was defined [4]. An autoimmune antibody reacting to myelin glycoproteins of peripheral nerves has been proposed as a mechanism of Guillain-Barré Syndrome(GBS) [5]. GBS associated with COVID infection raises consideration of COVID triggering possible autoimmunity and similarly induced autoimmunity which might be the pathogenesis of myelitis associated with COVID. To the best of our knowledge, here in the present study, we have reported the first para infection post-COVID; longitudinally extensive transverse myelitis(LETM). It seems post-COVID CNS autoimmunity is a possible concern after the initial presentation of COVID.
  2 in total

1.  Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.

Authors:  He S Yang; Sabrina E Racine-Brzostek; Mohsen Karbaschi; Jim Yee; Alicia Dillard; Peter A D Steel; William S Lee; Kathleen A McDonough; Yuqing Qiu; Thomas J Ketas; Eric Francomano; P J Klasse; Layla Hatem; Lars F Westblade; Heng Wu; Haode Chen; Robert Zuk; Hong Tan; Roxanne Girardin; Alan P Dupuis; Anne F Payne; John P Moore; Melissa M Cushing; Amy Chadburn; Zhen Zhao
Journal:  medRxiv       Date:  2020-11-22

2.  Guillain-Barré Syndrome Associated with SARS-CoV-2.

Authors:  Gianpaolo Toscano; Francesco Palmerini; Sabrina Ravaglia; Luigi Ruiz; Paolo Invernizzi; M Giovanna Cuzzoni; Diego Franciotta; Fausto Baldanti; Rossana Daturi; Paolo Postorino; Anna Cavallini; Giuseppe Micieli
Journal:  N Engl J Med       Date:  2020-04-17       Impact factor: 91.245

  2 in total
  20 in total

1.  Post COVID-19 transverse myelitis; a case report with review of literature.

Authors:  Shwan Abubakr Ahmad; Karokh H Salih; Shaho Fatah Ahmed; Fahmi H Kakamad; Abdulwahid M Salh; Marwan Nasih Hassan; Karukh K Mohammed; Shvan H Mohammed; Rawezh Q Salih; Dahat A Hussein
Journal:  Ann Med Surg (Lond)       Date:  2021-08-23

2.  Acute Ascending Necrotizing Myelitis After COVID-19 Infection: A Clinicopathologic Report.

Authors:  Luis Guada; Franklyn Rocha Cabrero; Nicole L Baldwin; Allan D Levi; Sakir H Gultekin; Ashok Verma
Journal:  Neurol Clin Pract       Date:  2022-06

Review 3.  COVID-19-Associated Myelitis Involving the Dorsal and Lateral White Matter Tracts: A Case Series and Review of the Literature.

Authors:  H Y Huang; L M Shah; J S McNally; T Sant; T A Hutchins; E D Goldstein; M E Peckham
Journal:  AJNR Am J Neuroradiol       Date:  2021-08-19       Impact factor: 4.966

4.  Myelitis Following COVID-19 Illness.

Authors:  Nihal Gulati; Saniya Kapila; Lucky Bhalla Sehgal; Vineet Sehgal; Priyal Lnu
Journal:  Cureus       Date:  2022-08-18

Review 5.  Neurologic Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Authors:  Avindra Nath
Journal:  Continuum (Minneap Minn)       Date:  2021-08-01

6.  Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222).

Authors:  Gustavo C Román; Fernando Gracia; Antonio Torres; Alexis Palacios; Karla Gracia; Diógenes Harris
Journal:  Front Immunol       Date:  2021-04-26       Impact factor: 7.561

Review 7.  COVID-19 associated brain/spinal cord lesions and leptomeningeal enhancement: A meta-analysis of the relationship to CSF SARS-CoV-2.

Authors:  Ariane Lewis; Rajan Jain; Jennifer Frontera; Dimitris G Placantonakis; Steven Galetta; Laura Balcer; Kara R Melmed
Journal:  J Neuroimaging       Date:  2021-06-08       Impact factor: 2.324

Review 8.  Cerebrospinal fluid in COVID-19: A systematic review of the literature.

Authors:  Ariane Lewis; Jennifer Frontera; Dimitris G Placantonakis; Jennifer Lighter; Steven Galetta; Laura Balcer; Kara R Melmed
Journal:  J Neurol Sci       Date:  2021-01-10       Impact factor: 3.181

9.  Systematic review of cases of acute myelitis in individuals with COVID-19.

Authors:  Eva C Schulte; Larissa Hauer; Alexander B Kunz; Johann Sellner
Journal:  Eur J Neurol       Date:  2021-07-12       Impact factor: 6.288

10.  SARS-CoV-2, the autoimmune virus.

Authors:  Gilad Halpert; Yehuda Shoenfeld
Journal:  Autoimmun Rev       Date:  2020-10-28       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.